G1 Therapeutics, Inc. (GTHX)
Sep 18, 2024 - GTHX was delisted (acquired by Pharmacosmos)
7.15
0.00 (0.00%)
Inactive · Last trade price on Sep 17, 2024

G1 Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Net Income
-44.77-47.97-147.56-148.35-99.25-122.45
Depreciation & Amortization
0.490.510.530.470.580.36
Other Amortization
1.251.472.231.110.62-
Loss (Gain) From Sale of Assets
----0.32-
Loss (Gain) From Sale of Investments
-2.41-2.27-0.45---
Stock-Based Compensation
11.514.5120.5922.3218.7716.45
Other Operating Activities
1.380.611.351.18-0.7-
Change in Accounts Receivable
-0.14-1.59-5.41-5.45-0.24-
Change in Inventory
2.223.74-12.71-3.47--
Change in Accounts Payable
-0.22-3.374.42-0.68-0.240.25
Change in Unearned Revenue
0.310.11-0.020.790.24-
Change in Other Net Operating Assets
-7.15-4.098.41-0.04-3.835.82
Operating Cash Flow
-37.54-38.34-128.62-132.11-83.74-99.57
Capital Expenditures
---0.51---2.72
Sale of Property, Plant & Equipment
0---0.15-
Investment in Securities
5.072.81-50.02---
Investing Cash Flow
5.072.81-50.53-0.15-2.72
Long-Term Debt Issued
---5520-
Long-Term Debt Repaid
--26.69----
Net Debt Issued (Repaid)
-8.75-26.69-5520-
Issuance of Common Stock
0.310.0652.5492.272.312.71
Other Financing Activities
--0.28-0.04-1.41-0.62-
Financing Cash Flow
-8.43-26.9152.5145.8621.692.71
Net Cash Flow
-40.9-62.44-126.6513.76-61.9-99.58
Free Cash Flow
-37.54-38.34-129.13-132.11-83.74-102.29
Free Cash Flow Margin
-64.51%-46.46%-251.70%-419.71%-184.92%-
Free Cash Flow Per Share
-0.72-0.74-2.96-3.15-2.21-2.73
Cash Interest Paid
6.968.817.922.911-
Levered Free Cash Flow
-19.83-19.99-72.86-77.17-44.38-60.79
Unlevered Free Cash Flow
-15.49-15.19-68.57-75.37-43.88-60.79
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q